Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis

References

• Pandey A, Kalita KN. Treatment-resistant schizophrenia: how far have we traveled? Front Psychiatry. 2022 Sep 17;13:994425. doi: 10.3389/fpsyt.2022.994425
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Jul 3;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Nov 10(11):CD006633. doi: 10.1002/14651858.CD006633.pub2
   PubMed Web of Science ®Google Scholar
• Flanagan RJ, Lally J, Gee S, et al. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. Br Med Bull. 2020 Sep 5;135(1):73–89. doi: 10.1093/bmb/ldaa024
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment. Expert Opin Pharmacother. 2019 Nov 9;20(1):11–24.
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016 Jun 11;173(9):876–886. doi: 10.1176/appi.ajp.2016.15081035
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016 Feb 5;73:199–210. doi: 10.1001/jamapsychiatry.2015.2955
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):4. doi: 10.1186/2046-4053-4-1
   PubMedGoogle Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162:777–784. doi: 10.7326/M14-2385
   PubMed Web of Science ®Google Scholar
• Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019 Mar 5;80(2):18com12123. doi: 10.4088/JCP.18com12123
   PubMed Web of Science ®Google Scholar
• 4.6 W. Web plot digitizer. 2022. Available from: https://automeris.io/WebPlotDigitizer/.
   Google Scholar
• van Valkenhoef GK. gemtc: network meta-analysis using Bayesian methods. Available from: https://CRAN.R-project.org/package=gemtc (2021).
   Google Scholar
• Adelino MPM, Nunes MV, Nunes MFQ, et al. Treatment-resistant schizophrenia - A RCT on the effectiveness of repeated-dose sodium nitroprusside. Schizophr Res. 2021 Mar 28;231:70–72. doi: 10.1016/j.schres.2021.03.005
   PubMed Web of Science ®Google Scholar
• Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001 Aug 2;158(8):1305–1313. doi: 10.1176/appi.ajp.158.8.1305
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The risperidone study group. Am J Psychiatry. 1998 Apr 18;155(4):499–504. doi: 10.1176/ajp.155.4.499
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994 Jan 1;151:20–26. doi: 10.1176/ajp.151.1.20
   PubMed Web of Science ®Google Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999 Mar 11;45(4):403–411.
   PubMed Web of Science ®Google Scholar
• Brunstein MG, Ghisolfi ES, Ramos FL, et al. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry. 2005 Feb 12;66(2):213–219. doi:10.4088/jcp.v66n0209
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998 Jun 10;155(6):751–760. doi: 10.1176/ajp.155.6.751
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 2005 [2004 Dec 31];162(1):124–129. doi: 10.1176/appi.ajp.162.1.124
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998 Jul 11;155(7):914–920. doi: 10.1176/ajp.155.7.914
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005 Aug 3;28(4):163–168. doi: 10.1097/01.wnf.0000172993.89879.0f
   PubMed Web of Science ®Google Scholar
• Ding N, Li Z, Liu Z. Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients - a randomized controlled trial. Neurosci Lett. 2018 Jun 1;681: 68–72. doi: 10.1016/j.neulet.2018.05.030
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al.; PRIZE Study Group. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000 Jun 28;15(3):121–131. doi: 10.1097/00004850-200015030-00001
   PubMed Web of Science ®Google Scholar
• Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007 Nov 16;27(6):582–589. doi: 10.1097/jcp.0b013e31815abf34
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996 Nov 1;169:610–617.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999 Jan 19;56:29–36. doi: 10.1001/archpsyc.56.1.29
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Shimoni J, et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002 Mar 1;159(3):480–482. doi: 10.1176/appi.ajp.159.3.480
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004 Jan 21;55(2):165–171. doi: 10.1016/s0006-3223(03)00707-8
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005 Mar 23;57(6):577–585. doi: 10.1016/j.biopsych.2004.12.037
   PubMed Web of Science ®Google Scholar
• Hong CJ, Chen JY, Chiu HJ, et al. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol. 1997 May 1;12(3):123–130. doi: 10.1097/00004850-199705000-00001
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep 1;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001
   PubMed Web of Science ®Google Scholar
• Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006 [2005 Dec 1];21:21–28. doi: 10.1097/01.yic.0000182114.65134.81
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, et al. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011 [2010 Aug 3];72:194–204. doi: 10.4088/JCP.07m03733yel
   PubMed Web of Science ®Google Scholar
• Kane JM, Kinon BJ, Forray C, et al. Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: a randomized, active-controlled trial with open-label extension. Schizophr Res. 2022 Sep 18;248:271–278. doi: 10.1016/j.schres.2022.09.012
   PubMed Web of Science ®Google Scholar
• Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol. 2004 Apr 23;19:23–26. doi: 10.1097/00004850-200401000-00004
   PubMed Web of Science ®Google Scholar
• Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004 Sep 15;56(6):441–446. doi: 10.1016/j.biopsych.2004.06.029
   PubMed Web of Science ®Google Scholar
• Kumar M, Chavan BS, Sidana A, et al. Efficacy and tolerability of clozapine versus Quetiapine in treatment-resistant schizophrenia. Indian J Psychol Med. 2017 Dec 30;39(6):770–776. doi: 10.4103/IJPSYM.IJPSYM_111_17
   PubMedGoogle Scholar
• Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006 Mar 17;32(4):715–723. doi: 10.1093/schbul/sbj067
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 Feb 1;69(2):274–285. doi: 10.4088/jcp.v69n0214
   PubMed Web of Science ®Google Scholar
• Meskanen K, Ekelund H, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2013 Jun 15;33(4):472–478. doi: 10.1097/JCP.0b013e3182970490
   PubMed Web of Science ®Google Scholar
• Miyaoka T, Furuya M, Horiguchi J, et al. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a positive and negative syndrome scale, five-factor analysis). Psychopharmacol (Berl). 2015 [2014 Jun 14];232:155–164. doi: 10.1007/s00213-014-3645-8
   PubMed Web of Science ®Google Scholar
• Moresco RM, Cavallaro R, Messa C, et al. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep 11;18:355–365. doi: 10.1177/026988110401800306
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012 [2011 Dec 27];32(1):95–99. doi: 10.1097/JCP.0b013e31823f913e
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. N Engl J Med. 1997 Sep 19;337:809–815. doi: 10.1056/NEJM199709183371202
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009 Jul 17;113(1):112–121. doi: 10.1016/j.schres.2009.05.002
   PubMed Web of Science ®Google Scholar
• Salehi A, Namaei P, TaghaviZanjani F, et al. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: a randomized, double-blinded, placebo-controlled trial. Psychiatry Res. 2022 Aug 3;316:114737. doi: 10.1016/j.psychres.2022.114737
   PubMed Web of Science ®Google Scholar
• See RE, Fido AA, Maurice M, et al. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry. 1999 Jun 22;45(12):1653–1656. doi: 10.1016/s0006-3223(98)00199-1
   PubMed Web of Science ®Google Scholar
• Shi H, Xu J, Lang X, et al. Comparison of efficacy and safety between low-dose ziprasidone in combination with sertraline and ziprasidone monotherapy for treatment-resistant patients with acute exacerbation schizophrenia: a randomized controlled trial. Front Pharmacol. 2022 May 14;13:863588. doi: 10.3389/fphar.2022.863588
   PubMed Web of Science ®Google Scholar
• Shiloh R, Zemishlany Z, Aizenberg D, et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol. 2002 Mar 14;17(2):59–64. doi: 10.1097/00004850-200203000-00003
   PubMed Web of Science ®Google Scholar
• Sirota P, Pannet I, Koren A, et al. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol. 2006 Jun 6;21(4):227–234. doi: 10.1002/hup.763
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001 Feb 13;49(1):52–63. doi: 10.1016/s0006-3223(00)01026-x
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Tuisku K, et al. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Oct 21;24(6):911–922. doi: 10.1016/s0278-5846(00)00118-4
   PubMed Web of Science ®Google Scholar
• Wang D, Wei N, Hu F, et al. Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: a Randomized, Double-Blind, Multicenter Study. J Clin Psychopharmacol. 2022 Jun 14;42:383–390. doi: 10.1097/JCP.0000000000001573
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Marshall BD Jr., Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999 Sep 15;156(9):1374–1379. doi: 10.1176/ajp.156.9.1374
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, et al. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol. 2001 Nov 20;16(6):325–330. doi: 10.1097/00004850-200111000-00002
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Kang WH, Li Q, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006 Sep 9;88(1–3):102–110. doi: 10.1016/j.schres.2006.07.010
   PubMed Web of Science ®Google Scholar
• Zhuo C, Xu Y, Wang H, et al. Safety and efficacy of high-dose vitamin B6 as an adjunctive treatment for antipsychotic-induced hyperprolactinemia in male patients with treatment-resistant schizophrenia. Front Psychiatry. 2021 Sep 14;12:681418. doi: 10.3389/fpsyt.2021.681418
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Jul 16;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001 Apr 3;158(4):518–526. doi: 10.1176/appi.ajp.158.4.518
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999 Jul 13;156(7):990–999. doi: 10.1176/ajp.156.7.990
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Manchia M, Marmo F, et al. Glycine signaling in the framework of dopamine-glutamate interaction and postsynaptic density. Implications for treatment-resistant schizophrenia. Front Psychiatry. 2020 Jun 2;11:369. doi: 10.3389/fpsyt.2020.00369
   PubMed Web of Science ®Google Scholar
• Mizuki Y, Kajimura N, Imai T, et al. Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1990 Apr 1;5(2):83–96. doi: 10.1097/00004850-199004000-00002
   PubMed Web of Science ®Google Scholar
• Yu CH, Ishii R, Yu SC, et al. Yokukansan and its ingredients as possible treatment options for schizophrenia. Neuropsychiatr Dis Treat. 2014 Sep 12;10:1629–1634. doi: 10.2147/NDT.S67607
   PubMed Web of Science ®Google Scholar
• Marcus MM, Jardemark K, Malmerfelt A, et al. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence. The Synapse. 2012 [2011 Nov 29];66:277–290. doi: 10.1002/syn.21510
   PubMed Web of Science ®Google Scholar
• Ali C, Nicole O, Docagne F, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab. 2000 Jul 14;20(6):956–966. doi: 10.1097/00004647-200006000-00008
   PubMed Web of Science ®Google Scholar